10-Q: Teladoc Health Q3 2025: Revenue Dip, Goodwill Impairments

Teladoc Health reports a 2% revenue decrease for Q3 2025, alongside significant goodwill impairments and a net loss, despite growth in U.S. Integrated Care members.

Summary

• Total revenue decreased by 2% to $626.4 million for the three months ended September 30, 2025, compared to $640.5 million in the prior year period.
• For the nine months ended September 30, 2025, total revenue decreased by 2% to $1,887.7 million, down from $1,929.1 million in the same period of 2024.
• Net loss for the three months ended September 30, 2025, was $49.5 million, an increase from a net loss of $33.3 million in the comparable 2024 period.
• Net loss for the nine months ended September 30, 2025, significantly improved to $175.2 million, compared to a net loss of $952.8 million in the prior year, primarily due to lower goodwill impairments.
• Adjusted EBITDA decreased by 16% to $69.9 million for the three months ended September 30, 2025, and by 16% to $197.3 million for the nine months ended September 30, 2025.
• U.S. Integrated Care members increased by 9% to 102.5 million at September 30, 2025, compared to the same period in 2024.
• Chronic Care Program Enrollment decreased by 1% to 1.165 million at September 30, 2025, from 1.179 million at September 30, 2024.
• BetterHelp paying users decreased by 4% to 0.382 million for the three months ended September 30, 2025, and by 4% to 0.389 million for the nine months ended September 30, 2025.
• Goodwill impairments of $12.6 million for the three months ended September 30, 2025, and a year-to-date total of $71.8 million were recognized, primarily from the Telecare and Catapult Health acquisitions.
• Cash and cash equivalents were $726.2 million as of September 30, 2025, a decrease from $1,298.3 million at December 31, 2024.
• The company repaid $550.6 million in convertible senior notes during the nine months ended September 30, 2025.
• A new five-year, $300.0 million senior secured revolving credit facility was entered into on July 17, 2025.

Sentiment

Score: 3

Explanation: The company experienced revenue declines, increased quarterly net loss, and reduced profitability (Adjusted EBITDA) driven by underperforming BetterHelp and chronic care segments, coupled with significant goodwill impairments from recent acquisitions. While Integrated Care showed growth and cost controls were evident, the overall financial performance and user metric declines are concerning.

Positives

• U.S. Integrated Care members increased by 8.6 million, or 9%, to 102.5 million at September 30, 2025, compared to the same period in 2024.
• Integrated Care segment revenue increased by 2% to $389.5 million for the three months ended September 30, 2025, and by 3% to $1,170.5 million for the nine months ended September 30, 2025.
• Net loss significantly improved for the nine months ended September 30, 2025, to $175.2 million from $952.8 million in the prior year, largely due to lower goodwill impairments compared to the previous year.
• Restructuring costs decreased by 46% to $2.0 million for the three months ended September 30, 2025, and by 19% to $12.0 million year-to-date.
• Advertising and marketing expenses decreased by 5% for both the three and nine months ended September 30, 2025, indicating cost control.
• Technology and development expenses decreased by 7% for the three months ended September 30, 2025, and by 11% year-to-date.
• General and administrative expenses decreased by 10% for the three months ended September 30, 2025, and by 4% year-to-date.
• Free cash flow remained stable at $113.5 million for the nine months ended September 30, 2025, compared to $113.4 million in the prior year.
• Secured a new five-year, $300.0 million senior secured revolving credit facility, enhancing financial flexibility.
• Realized discrete tax benefits of $20.1 million related to a research and development tax credit study and $11.1 million from current year acquisitions.

Negatives

• Total revenue decreased by 2% for both the three and nine months ended September 30, 2025, primarily driven by lower revenue in the BetterHelp segment.
• Net loss increased by 49% to $49.5 million for the three months ended September 30, 2025, compared to $33.3 million in the prior year period.
• Adjusted EBITDA decreased by 16% for both the three and nine months ended September 30, 2025.
• BetterHelp paying users decreased by 4% for both the three and nine months ended September 30, 2025.
• BetterHelp total revenue decreased by 8% for the three months ended September 30, 2025, and by 9% year-to-date.
• Chronic Care Program Enrollment decreased by 1% to 1.165 million.
• Average monthly revenue per U.S. Integrated Care member decreased to $1.27 in the three months ended September 30, 2025, from $1.36 in the same period in 2024.
• Goodwill impairments of $12.6 million for Q3 2025 and $71.8 million year-to-date were recognized from recent acquisitions (Telecare and Catapult Health), indicating potential overpayment or underperformance.
• Cash and cash equivalents significantly decreased from $1,298.3 million at December 31, 2024, to $726.2 million at September 30, 2025, largely due to debt repayment and acquisitions.
• Interest income decreased by 54% for the three months ended September 30, 2025, and 30% year-to-date, driven by lower interest rate yields and a lower average balance of cash and cash equivalents.

Risks

• Dependence on a limited number of third-party suppliers for certain components of medical devices, where the loss of any supplier or their inability to provide adequate supply could harm the business.
• International operations pose political, legal, compliance, operational, regulatory, economic, and other risks that may be different from or more significant than domestic operations, and exposure to these risks is expected to increase.
• Operating in a competitive industry where health plans may develop solutions that replicate or offer competitive services at discounted prices, potentially resulting in a loss of members.
• A significant portion of revenue comes from a limited number of clients, the loss of which could have a material adverse effect on the business.
• Sustained significant decreases in share price may result in the need to perform future impairment assessments of goodwill and long-lived assets, including definite-lived intangibles.
• Uncertainty regarding the impact of tariffs and changes to global trade policies, including retaliatory tariffs, on consolidated results of operations, particularly for imported components.
• Future capital requirements depend on various factors including growth rate, contract renewal activity, member retention, product development, sales and marketing expansion, new service offerings, market acceptance of telehealth, and debt service obligations.
• In the event additional financing is required from outside sources, the company may not be able to raise it on acceptable terms or at all, which would adversely affect the business.
• Ongoing legal proceedings, including multiple securities class actions and a patent infringement lawsuit, could result in material adverse impacts on the business, financial condition, results of operations, or cash flows.

Future Outlook

The company anticipates continuing positive operating cash flows for 2025 and believes its existing cash and cash equivalents will be sufficient to meet working capital, capital expenditure, and contractual obligation needs for at least the next 12 months. Future capital requirements will depend on growth rate, contract renewal activity, member retention, product development efforts, expansion of sales and marketing activities, introduction of new and enhanced services, market acceptance of telehealth, and debt service obligations. The company may seek additional equity or debt financing in the future to fund working capital, capital expenditures, acquisitions, and debt settlements. Initiatives to improve efficiency and competitiveness, optimize operational costs, and streamline processes and branding are currently being evaluated, with related charges expected to begin recognizing in the three months ending December 31, 2025.

Management Comments

• Our mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience.
• We have a vision of making virtual care the first step on any healthcare journey, and we are delivering on this mission by providing virtual care that includes primary care, mental health, chronic condition management, and more.
• We believe that our ability to add new members and retain existing members, and to increase utilization and penetration further into existing and new health plan and employer Clients is a key indicator of our increasing market adoption, the growth of our business, and our future revenue potential.
• We believe that our ability to increase the revenue generated from each member over time is also a key indicator of our increasing market adoption, the growth of our business, and future revenue potential.
• Effectively reaching potential paying users through various advertising channels remains critical to our success.
• We believe that our existing cash and cash equivalents will be sufficient to meet our working capital, capital expenditure, and contractual obligation needs for at least the next 12 months.
• We do not currently anticipate borrowing any amounts under the Revolving Credit Facility.

Industry Context

The virtual care industry continues to evolve, with Teladoc Health positioning itself as a global leader. The company faces intense competition, particularly from health plans that are developing their own virtual care solutions or offering competitive services at discounted prices, which could impact membership and revenue. The decline in BetterHelp paying users and chronic care program enrollment suggests challenges in specific segments of the virtual health market, potentially due to increased competition, market saturation, or shifts in consumer behavior. The strategic focus on growing Integrated Care members and increasing revenue per member indicates an effort to deepen engagement within existing client relationships, a common strategy in mature subscription-based healthcare models. The impact of tariffs and global trade policies is a broader macroeconomic factor affecting companies with international supply chains, particularly for medical devices, adding a layer of uncertainty to operational costs.

Comparison to Industry Standards

• NA

Management Changes

Legal Proceedings

• Schneider v. Teladoc Health, Inc., et al. (Securities Class Action): Filed June 6, 2022, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The court granted a renewed motion to dismiss on March 21, 2025, but the lead plaintiff filed an appeal on July 25, 2025.
• Multiple Putative Class-Action Lawsuits against BetterHelp: Filed in California federal and state courts and in Canada, related to a July 2023 FTC consent order, alleging misleading patients about data use and privacy violations.
• Data Health Partners, Inc. v. Teladoc Health, Inc. (Patent Infringement): Filed February 13, 2023, alleging that certain products, including a blood glucose meter, infringe upon patents held by Data Health Partners.
• Stary v. Teladoc Health, Inc., et al. (Securities Class Action): Filed May 17, 2024, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, based on allegedly false or misleading statements regarding advertising spend on BetterHelp. An amended complaint was filed on February 24, 2025, and a motion to dismiss was filed on June 20, 2025.
• Roy v. Gorevic, et al. (Shareholder Derivative Complaint): Filed June 18, 2024, asserting violations of Sections 10(b) and 14(a) of the Securities Exchange Act of 1934, breach of fiduciary duty, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control. Proceedings are stayed pending resolution of the related securities class action.
• Brigman, et al. v. Daniel, et al. (Shareholder Derivative Complaint): Filed October 1, 2024, similar to Roy, also alleging insider trading violations and misappropriation of information. Proceedings are stayed pending resolution of the related securities class action.

Stakeholder Impact

• Shareholders: Potential negative impact due to revenue decline, increased quarterly net loss, decreased Adjusted EBITDA, significant goodwill impairments, and ongoing legal proceedings. The CFO's resignation adds to leadership uncertainty.
• Employees: Restructuring costs of $1.7 million for Q3 2025 and $10.6 million year-to-date related to employee transition, severance, and benefits indicate workforce reductions.
• Customers (Clients/Members): Mixed impact with an increase in U.S. Integrated Care members but decreases in chronic care enrollment and BetterHelp paying users. Concerns exist regarding competitive offerings from health plans.
• Suppliers: Dependence on a limited number of third-party suppliers for medical devices poses a risk to the supply chain.
• Creditors: The repayment of $550.6 million in convertible senior notes and the establishment of a new $300.0 million revolving credit facility impact the company's debt structure and liquidity position.

Next Steps

• Continue evaluating initiatives to improve efficiency and competitiveness, optimize operational costs, and streamline processes and branding.
• Expects to begin recognizing charges associated with these efficiency and competitiveness initiatives in the three months ending December 31, 2025.
• Management intends to vigorously defend ongoing legal proceedings, including multiple securities class actions and a patent infringement lawsuit.
• Charles Divita, III, the Chief Executive Officer, will serve as principal financial officer following Mala Murthy's resignation until a new Chief Financial Officer is appointed.
• Kelly Bliss, President, U.S. Group Health, has adopted a Rule 10b5-1 trading plan for the sale of up to 10,000 shares of common stock through December 2026.
• Kenneth H. Paulus, a Board member, has adopted a Rule 10b5-1 trading plan for the purchase of up to 10,000 shares of common stock through November 2025.

Key Dates

Recommendation

The filing reveals a concerning trend of declining revenue and profitability, particularly in the BetterHelp segment, which is a significant growth driver. The substantial goodwill impairments from recent acquisitions suggest poor capital allocation or underperformance of acquired assets. While the Integrated Care segment shows some growth and cost controls were evident, the overall financial deterioration, coupled with a significant reduction in cash and cash equivalents and ongoing legal challenges, indicates fundamental operational and strategic issues. The CFO's resignation adds to leadership uncertainty. These factors collectively point to a challenging outlook, making the stock a 'Sell' for a seasoned investor.

Keywords

Virtual care, Telehealth, Digital health, Chronic care management, Mental health, SEC filing, 10-Q, Financial results, Teladoc Health, TDOC, Healthcare technology, Goodwill impairment, Revenue, EBITDA, Cash flow, Acquisitions, Legal proceedings, Corporate governance, Risk management